Neurol. praxi. 2023;24(4):286-292 | DOI: 10.36290/neu.2023.057

Novel treatment for myasthenia gravis

MUDr. Michaela Týblová, Ph.D.
Neurologická klinika a Centrum klinických neurověd, 1. LF UK a VFN v Praze

Myasthenia gravis (MG) is a rare autoimmune disease characterized by muscle weakness and fatigue. In addition to the currently used non-specifically acting immunomodulating treatment, new specific immunotherapeutics has significantly expanded in recent years. This includes inhibitors of the C5 complement protein, blockers of the neonatal Fc receptor, drugs that cause depletion of B and T lymphocytes and others. The great advantage of all these medicinal products is a faster effect and a significantly lower incidence of side effects. A significant limitation of their use in normal clinical practice may be their expected high price.

Keywords: generalized myasthenia gravis, blockers of neonatal Fc receptors, complement inhibitors, B cell depleting agents, genetically modifying T cells.

Accepted: August 24, 2023; Published: September 8, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Týblová M. Novel treatment for myasthenia gravis. Neurol. praxi. 2023;24(4):286-292. doi: 10.36290/neu.2023.057.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current Treatment of Myasthenia Gravis. J Clin Med. 2022;11(6):1957. doi:10.3390/jcm11061597. Go to original source... Go to PubMed...
    2. Alabbad S, AlGaeed M, Sikorski P, Kaminski HJ. Monoclonal Antibody-Based Therapies for Myasthenia Gravis. BioDrugs. 2020;34(5):557-566. doi:10.1007/s40259-020-00443-w. Go to original source... Go to PubMed...
    3. Beecher G, Putko BN, Wagner AN, Siddiqi ZA. Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status. Drugs. 2019;79(4):353-364. doi:10.1007/s40265-019-1065-0. Go to original source... Go to PubMed...
    4. Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22(5):383-394. doi:10.1016/S1474-4422(23)00077-7. Go to original source... Go to PubMed...
    5. Chen Y, Sun J, Liu H, et al. Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases. J Immunol Res. 2019;20195727516. doi:10.1155/2019/5727516. Go to original source... Go to PubMed...
    6. Devalaraja-Narashimha K, Huang C, Cao M, et al. Pharmacokinetics and pharmacodynamics of pozelimab alone or in combination with cemdisiran in non-human primates. PLoS One. 2022;17(6):e0269749. doi:10.1371/journal.pone.0269749. Go to original source... Go to PubMed...
    7. Harris L, Allman PH, Sheffield R, Cutter G. Longitudinal Analysis of Disease Burden in Refractory and Nonrefractory Generalized Myasthenia Gravis in the United States. J Clin Neuromuscul Dis. 2020;22(1).11-21. doi:10.1097/CND.0000000000000301. Go to original source... Go to PubMed...
    8. Hewett K, Sanders DB, Grove RA, et al. Randomized study of adjunctive belimumab in participants with generalized myasthenia gravis. Neurology. 2018;90(16):e1425-e1434. doi:10.1212/WNL.0000000000005323. Go to original source... Go to PubMed...
    9. Howard J, Bril V, Vu T, et al. Efficacy, Safety, and Tolerability of Efgartigimod in Patients With Generalized Myasthenia Gravis: Analysis of the Phase 3 ADAPT Study (4520). Neurology. 2021;96(15 Supplement). Go to original source... Go to PubMed...
    10. Howard JF, Bresch S, Genge A, et al. Safety and Efficacy of Zilucoplan in Patients with Generalised Myasthenia Gravis (RAISE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. The Lancet Neurology. 2023;22(5):395-406. https://doi.org/10.1016/S1474-4422(23)00080-7. Go to original source... Go to PubMed...
    11. Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976-986. doi:10.1016/S1474-4422(17)30369-1. Go to original source... Go to PubMed...
    12. Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Ann Thorac Surg. 2000;70(1):16-23. doi:10.1212/wnl.55.1.16. Go to original source... Go to PubMed...
    13. Lysák D. Imunoterapie pomocí CAR T-lymfocytů. Onkologie. 2015;9(1):13-18.
    14. Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: Clinical signposts and treatment strategies. Ther Adv Neurol Disord. 2018;11. doi:10.1177/1756285617749134. Go to original source... Go to PubMed...
    15. McKeage K. Ravulizumab: First Global Approval. Drugs. 2019;79(3):347-352. doi:10.1007/s40265-019-01068-2. Go to original source... Go to PubMed...
    16. Menon D, Barnett C, Bril V. Novel Treatments in Myasthenia Gravis. Front Neurol. 2020;11. doi:10.3389/fneur.2020.00538. Go to original source... Go to PubMed...
    17. Menon D, Bril V. Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. Drugs. 2022;82(8):865-887. doi:10.1007/s40265-022-01726-y. Go to original source... Go to PubMed...
    18. Murai H, Uzawa A, Suzuki Y, et al. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study. J Neurol Sci. 2019;407:116419. doi:10.1016/j.jns.2019.08.004. Go to original source... Go to PubMed...
    19. Narayanaswami P, Sanders DB, Wolfe G, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology. 2021;96(3):114-122. doi:10.1212/WNL.0000000000011124. Go to original source... Go to PubMed...
    20. Ndegwa S, Mierzwinski-Urban M. Emerging Drugs for Generalized Myasthenia Gravis. Can J Heal Technol. 2022;2(2):114-122. doi:10.51731/cjht.2022.270. Go to original source...
    21. Nowak RJ, Coffey CS, Goldstein JM, et al. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. Neurology. 2022;98(4):e376-e389. doi:10.1212/WNL.0000000000013121. Go to original source... Go to PubMed...
    22. Oh S, O'Connor K, Payne A. MuSK Chimeric Autoantibody Receptor (CAAR) T Cells for Antigen-specific Cellular Immunotherapy of Myasthenia Gravis (2769). Neurology. 2020;94(15 Supplement). Go to original source...
    23. Sánchez-Tejerina D, Sotoca J, Llaurado A, et al. New Targeted Agents in Myasthenia Gravis and Future Therapeutic Strategies. J Clin Med. 2022;11(21):6394. doi:10.3390/jcm11216394. Go to original source... Go to PubMed...
    24. Schneider-Gold C, Reinacher-Schick A, Ellrichmann G, Gold R. Bortezomib in severe MuSK-antibody positive myasthenia gravis: First clinical experience. Ther Adv Neurol Disord. 2017;10(10):339-341. doi:10.1177/1756285617721093. Go to original source... Go to PubMed...
    25. SÚKL Státní ústav pro kontrolu léčiv [online]. Dostupné z: https://prehledy.sukl.cz/.
    26. Tandan R, Hehir MK, Waheed W, Howard DB. Rituximab treatment of myasthenia gravis: A systematic review. Muscle and Nerve. 2017;56(2):185-196. doi:10.1002/mus.25597. Go to original source... Go to PubMed...
    27. Tannemaat MR, Verschuuren JJGM. Emerging therapies for autoimmune myasthenia gravis: Towards treatment without corticosteroids. Neuromuscul Disord. 2020;30(2):111-119. doi:10.1016/j.nmd.2019.12.003. Go to original source... Go to PubMed...
    28. Týblová M. Current and future therapeutic options for the treatment of the generalized form of myasthenia gravis. Ces a Slov Neurol a Neurochir. 2023;86(2):100-106. doi:10.48095/cccsnn2023100. Go to original source...
    29. U.S. National Library of Medicine [online]. Dostupné z: https:// classic.clinicaltrials.gov/.
    30. Ward ES, Gelinas D, Dreesen E, et al. Clinical Significance of Serum Albumin and Implications of FcRn Inhibitor Treatment in IgG-Mediated Autoimmune Disorders. Front Immunol. 2022;13(June):1-13. doi:10.3389/fimmu.2022.892534. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.